Atlas Trials

Beijing Boren Hospital

24 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Beijing Boren Hospital

RecordFirmDate
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma (NCT07555561)Beijing Boren Hospital2026-09-01
A Study of BEN301 Injection in the Treatment of Autoimmune Diseases (NCT07502859)Beijing Boren Hospital2026-03-25
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases (NCT07448298)Beijing Boren Hospital2026-03-09
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases (NCT07361094)Beijing Boren Hospital2025-11-06
FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients. (NCT07604792)Beijing Boren Hospital2025-09-25
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis (NCT06983951)Beijing Boren Hospital2025-02-20
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases (NCT06993493)Beijing Boren Hospital2025-02-20
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases (NCT06983964)Beijing Boren Hospital2025-02-20
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis (NCT07626476)Beijing Boren Hospital2024-12-16
A Study of CAR-T Cells Targeting Autoimmune Diseases (NCT06661811)Beijing Boren Hospital2024-11-15
Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19 (NCT05675943)Beijing Boren Hospital2023-01-12
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT05410041)Beijing Boren Hospital2022-05-25
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children (NCT04325841)Beijing Boren Hospital2022-03-24
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia (NCT05248685)Beijing Boren Hospital2022-02-16
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors (NCT05271279)Beijing Boren Hospital2021-12-24
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (NCT05266950)Beijing Boren Hospital2021-12-13
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma (NCT04689659)Beijing Boren Hospital2021-12-01
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (NCT05032599)Beijing Boren Hospital2021-09-14
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma (NCT04840875)Beijing Boren Hospital2021-09-14
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT04835519)Beijing Boren Hospital2021-04-08
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (NCT04340167)Beijing Boren Hospital2020-05-01
Study of Sequential CAR-T Cell Treating Leukemia Children (NCT04340154)Beijing Boren Hospital2020-05-01

Track Beijing Boren Hospital automatically

Every clearance here is in the API, with alerts when new ones post.